Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RECQL | P46063 | 1/20 | 0.84 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.80 |
| ▸ | PTAFR | P25105 | 1/20 | 0.80 |
| ▸ | HTR1D | P28221 | 1/20 | 0.80 |
| ▸ | HTR2C | P28335 | 1/20 | 0.80 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.80 |
| ▸ | DRD3 | P35462 | 1/20 | 0.80 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.80 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.77 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.77 |
| ▸ | NR5A2 | O00482 | 1/20 | 0.77 |
| ▸ | NR5A1 | Q13285 | 1/20 | 0.77 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.73 |
| ▸ | PRKCG | P05129 | 1/20 | 0.73 |
| ▸ | PRKCB | P05771 | 1/20 | 0.73 |
| ▸ | PRKCA | P17252 | 1/20 | 0.73 |
| ▸ | PRKCH | P24723 | 1/20 | 0.73 |
| ▸ | AKT1 | P31749 | 1/20 | 0.73 |
| ▸ | PRKCI | P41743 | 1/20 | 0.73 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2530513 | 1.00 | RECQL (0.84) | RECQLADRA1DPTAFRHTR1DHTR2C | |
| SCHEMBL2532131 | 1.00 | RECQL (0.84) | RECQLADRA1DPTAFRHTR1DHTR2C | |
| SCHEMBL434159 | 1.00 | RECQL (0.84) | RECQLADRA1DPTAFRHTR1DHTR2C | |
| SCHEMBL4661993 | 0.96 | RECQL (0.92) | RECQLADRA1DPTAFRHTR1DHTR2C | |
| SCHEMBL30690843 | 0.96 | RECQL (0.92) | RECQLADRA1DPTAFRHTR1DHTR2C | |
| SCHEMBL30547736 | 0.96 | RECQL (0.92) | RECQLADRA1DPTAFRHTR1DHTR2C | |
| SCHEMBL1394777 | 0.96 | RECQL (0.92) | RECQLADRA1DPTAFRHTR1DHTR2C | |
| SCHEMBL1428475 | 0.96 | RECQL (0.92) | RECQLADRA1DPTAFRHTR1DHTR2C | |
| SCHEMBL7217971 | 0.96 | RECQL (0.92) | RECQLADRA1DPTAFRHTR1DHTR2C | |
| SCHEMBL31443474 | 0.96 | RECQL (0.92) | RECQLADRA1DPTAFRHTR1DHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140287024-A1 | NANOPARTICLE-BASED DELIVERY SYSTEM WITH OXIDIZED PHOSPHOLIPIDS AS TARGETING LIGANDS FOR THE PREVENTION, DIAGNOSIS AND TREATMENT OF ATHEROSCLEROSIS | WANG SHU (US) | 2014-09-25 | — | — | US | claimed |
| US-20110230450-A1 | PLATELET-ACTIVATING FACTOR (PAF) ANALOGS AND USES THEREOF | Vascular Biogenics Lts (IL) | 2011-09-22 | — | — | US | claimed |
| US-7973023-B2 | Oxidized lipids and uses thereof in the treatment of inflammatory diseases and disorders | VASCULAR BIOGENICS LTD. (IL) | 2011-07-05 | — | — | US | claimed |
| US-7902176-B2 | Etherified oxidized phospholipids for inducing tolerance to oxidized LDL via mucosal administration; 1-hexadecyl-2-(5'-oxo-pentanyl)-sn-glycero-3-phosphocholine (D-ALLE) | VASCULAR BIOGENICS LTD. (IL) | 2011-03-08 | — | — | US | claimed |
| US-20100048515-A1 | Oxidized lipids and uses thereof in the treatment of inflammatory diseases and disorders | VASCULAR BIOGENICS LTD. (IL) | 2010-02-25 | — | — | US | claimed |
| EP-1626728-A4 | OXIDIZED LIPIDS AND USES THEREOF IN THE TREATMENT OF INFLAMMATORY DISEASES AND DISORDERS | VASCULAR BIOGENICS LTD (IL) | 2009-09-02 | — | — | EP | claimed |
| US-20080261865-A1 | Oxidized Lipids and Uses Thereof in the Treatment of Inflammatory Diseases and Disorders | VASCULAR BIOGENICS LTD. (IL) | 2008-10-23 | — | — | US | claimed |
| US-20070099868-A1 | Oxidized lipids and uses thereof in the treatment of inflammatory diseases and disorders | VASCULAR BIOGENICS LTD. (IL) | 2007-05-03 | — | — | US | claimed |
| EP-1626728-A2 | OXIDIZED LIPIDS AND USES THEREOF IN THE TREATMENT OF INFLAMMATORY DISEASES AND DISORDERS | Vascular Biogenics Ltd. (IL) | 2006-02-22 | — | — | EP | claimed |
| WO-2004106486-A2 | OXIDIZED LIPIDS AND USES THEREOF IN THE TREATMENT OF INFLAMMATORY DISEASES AND DISORDERS | VASCULAR BIOGENICS LTD. (IL) | 2004-12-09 | — | — | WO | claimed |
| US-12569439-B2 | Bottom-up assembly of synthetic extracellular vesicles | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2026-03-10 | — | — | US | disclosed |
| EP-4522646-A2 | APOE LIPOPROTEIN SYSTEMS | Kisbee Therapeutics, Inc. (US) | 2025-03-19 | — | — | EP | disclosed |
| WO-2023220387-A2 | APOE LIPOPROTEIN SYSTEMS | KISBEE THERAPEUTICS, INC. (US) | 2023-11-16 | — | — | WO | disclosed |
| US-20230181466-A1 | BOTTOM-UP ASSEMBLY OF SYNTHETIC EXTRACELLULAR VESICLES | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2023-06-15 | — | — | US | disclosed |
| US-20230038598-A1 | MICROFLUIDIC PRODUCTION OF BIOFUNCTIONALIZED GIANT UNILAMELLAR VESICLES FOR TARGETED CARGO DELIVERY | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2023-02-09 | — | — | US | disclosed |
| US-20080261865-A1 | Oxidized Lipids and Uses Thereof in the Treatment of Inflammatory Diseases and Disorders | VASCULAR BIOGENICS LTD. (IL) | 2008-10-23 | — | — | US | disclosed |
| US-20070099868-A1 | Oxidized lipids and uses thereof in the treatment of inflammatory diseases and disorders | VASCULAR BIOGENICS LTD. (IL) | 2007-05-03 | — | — | US | disclosed |
| US-20070077283-A1 | METHOD OF ENHANCING TRANSMUCOSAL DELIVERY OF THERAPEUTIC COMPOUNDS | NASTECH PHARMACEUTICAL COMPANY INC. | 2007-04-05 | — | — | US | disclosed |
| EP-1626728-A2 | OXIDIZED LIPIDS AND USES THEREOF IN THE TREATMENT OF INFLAMMATORY DISEASES AND DISORDERS | Vascular Biogenics Ltd. (IL) | 2006-02-22 | — | — | EP | disclosed |
| WO-2004106486-A2 | OXIDIZED LIPIDS AND USES THEREOF IN THE TREATMENT OF INFLAMMATORY DISEASES AND DISORDERS | VASCULAR BIOGENICS LTD. (IL) | 2004-12-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230038598-A1 | MICROFLUIDIC PRODUCTION OF BIOFUNCTIONALIZED GIANT UNILAMELLAR VESICLES FOR TARGETED CARGO DELIVERY | PCNA, BOD1L1, SARS1 | RECQL 539/4885ADRA1D 2519/4885PTAFR 3059/4885 |
| US-20070077283-A1 | METHOD OF ENHANCING TRANSMUCOSAL DELIVERY OF THERAPEUTIC COMPOUNDS | PGF, PLAT, PTAFR | RECQL 3257/4885ADRA1D 1551/4885PTAFR 3/4885 |
| US-20080261865-A1 | Oxidized Lipids and Uses Thereof in the Treatment of Inflammatory Diseases and Disorders | ALOX15B, GPX4, ALOX12 | RECQL 3800/4885ADRA1D 4010/4885PTAFR 1539/4885 |
| US-20110230450-A1 | PLATELET-ACTIVATING FACTOR (PAF) ANALOGS AND USES THEREOF | PLA2G7, PAFAH1B2, PAFAH1B3 | RECQL 2442/4885ADRA1D 1545/4885PTAFR 4/4885 |
| US-20100048515-A1 | Oxidized lipids and uses thereof in the treatment of inflammatory diseases and disorders | ALOX15B, GPX4, ALOX12 | RECQL 3800/4885ADRA1D 4010/4885PTAFR 1539/4885 |
| US-20070099868-A1 | Oxidized lipids and uses thereof in the treatment of inflammatory diseases and disorders | ALOX15B, GPX4, ALOX12 | RECQL 3800/4885ADRA1D 4010/4885PTAFR 1539/4885 |
| US-12569439-B2 | Bottom-up assembly of synthetic extracellular vesicles | EXOSC10, PLTP, EXOSC9 | RECQL 1850/4885ADRA1D 3085/4885PTAFR 39/4885 |
| US-20140287024-A1 | NANOPARTICLE-BASED DELIVERY SYSTEM WITH OXIDIZED PHOSPHOLIPIDS AS TARGETING LIGANDS FOR THE PREVENTION, DIAGNOSIS AND TREATMENT OF ATHEROSCLEROSIS | LDLR, APOB, MSR1 | RECQL 3693/4885ADRA1D 1380/4885PTAFR 52/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.